The safety of anidulafungin

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.

Original languageEnglish (US)
Pages (from-to)751-758
Number of pages8
JournalExpert Opinion on Drug Safety
Volume5
Issue number6
DOIs
StatePublished - Nov 1 2006

Fingerprint

anidulafungin
Echinocandins
Safety
Mycoses
Chemical Phenomena
Drug Interactions
Pharmaceutical Preparations
Fungi

Keywords

  • Anidulafungin
  • Echinocandin
  • Fungi
  • Glucan synthase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The safety of anidulafungin. / Vazquez, Jose Antonio.

In: Expert Opinion on Drug Safety, Vol. 5, No. 6, 01.11.2006, p. 751-758.

Research output: Contribution to journalReview article

@article{d61412ca1f7c4b8fbb2a69c1b5ae90dc,
title = "The safety of anidulafungin",
abstract = "The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.",
keywords = "Anidulafungin, Echinocandin, Fungi, Glucan synthase inhibitor",
author = "Vazquez, {Jose Antonio}",
year = "2006",
month = "11",
day = "1",
doi = "10.1517/14740338.5.6.751",
language = "English (US)",
volume = "5",
pages = "751--758",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - The safety of anidulafungin

AU - Vazquez, Jose Antonio

PY - 2006/11/1

Y1 - 2006/11/1

N2 - The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.

AB - The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.

KW - Anidulafungin

KW - Echinocandin

KW - Fungi

KW - Glucan synthase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33750553597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750553597&partnerID=8YFLogxK

U2 - 10.1517/14740338.5.6.751

DO - 10.1517/14740338.5.6.751

M3 - Review article

C2 - 17044802

AN - SCOPUS:33750553597

VL - 5

SP - 751

EP - 758

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -